Global Leaders in Migraine Research to Convene at The American Headache Society 61st Annual Scientific Meeting

MOUNT ROYAL, N.J., June 25, 2019 /PRNewswire/ -- At the American Headache Society (AHS) 61(st) Annual Scientific Meeting, leading researchers and clinicians specializing in migraine, cluster headache, post-traumatic headache, and other types of headache will present groundbreaking data on the basic and clinical science of these extraordinarily common and disabling diseases. Exciting advances in the treatment of migraine and cluster headache will be highlighted at the meeting, which takes place July 11 - July 14, 2019 in Philadelphia, Pennsylvania.

Dr. Andrew Charles, the Chair of the Scientific Program Committee for the meeting, will highlight some of the data being showcased during a Facebook Live event taking place on Thursday, July 11, 2019 at 9:00 am PDT/12:00 pm EDT. Join the conversation at: https://www.facebook.com/ahsheadache/

"The American Headache Society is honored to provide this forum for researchers and clinicians at the forefront of a tremendous sea change in the understanding and treatment of migraine and other headache disorders," said American Headache Society CEO Howard Rosen. "We look forward to welcoming more than 1,000 specialists from around the world to share ideas and experiences at our Annual Meeting, which will showcase more than 320 accepted scientific abstracts."

"We have entered a dramatically new era in headache medicine, in which new insights into the causes and consequences of migraine and other headache disorders have led to the development of remarkable new treatments," said Dr. Andrew Charles. "The data presented at the 61(st) AHS Annual Scientific Meeting will highlight our incredible progress including advances in treatment with anti-CGRP and neuromodulation devices, which are all part of the enthusiasm and optimism seen in our field today."

Migraine is one of the most common of all causes of disability worldwide, and represents a tremendous burden on individuals, families and healthcare systems. The diverse scientific and clinical data to be presented at the AHS Annual Scientific Meeting will bring us closer to the common goal of reducing this burden.

The AHS has a longstanding history of sponsoring innovative science, healthcare provider education and extensive involvement of its members in leading the most pivotal clinical trials. AHS is committed to improving the lives of those with migraine and works closely in conjunction with the American Migraine Foundation, a patient education and research arm founded by AHS in 2010.

Following is a select list of scheduled scientific presentations to be presented at the Annual Meeting. Note that all times are ET and subject to change:

Friday, July 12, 2019

    --  11:30 am - 11:40 amThe Relationship between Migraine and Risk of
        Cardiovascular Disease in Postmenopausal Women in the Observational
        Longitudinal Cohort of the Women's Health Initiative Study (WHI)Jelena
        Pavlovic, Md, PhD (ID Number OR01)




    --  11:40 am - 11:50 amPeroxynitrite Decomposition Catalysts Inhibit Acute
        Intracranial Dural-nociceptive Activation and Sensitisation of Central
        Trigeminovascular NeuronsSimon Akerman, PhD, FAHS (ID Number OR02)




    --  11:50 am - 12:00 pmA Randomized Trial of Telemedicine for Migraine
        ManagementDeborah I. Friedman, MD, MPH, FAHS (ID Number LBOR-01)




    --  12:00 pm - 12:10 pmAcute and Preventive Treatment Patterns in Episodic
        Cluster Headache: Findings from the United States, United Kingdom and
        GermanyJeffrey Scott Andrews, PharmD  (ID Number OR04)




    --  12:10 pm - 12:20 pmDemographics, Headache Characteristics, and Other
        Factors Associated with Opioid Use in People with Migraine: Results from
        the Chronic Migraine Epidemiology and Outcomes StudyTodd Schwedt, MD,
        MSCI, FAHS (OR05)




    --  12:20 pm - 12:30 pmAmerican Registry for Migraine Research: Methodology
        and Description of Initial CohortDavid Dodick, MD, FAHS (ID Number OR06)




    --  12:30 pm - 12:40 pmNoninvasive Vagus Nerve Stimulation Inhibits
        Trigeminal Nociception in Two Episodic Migraine Models by Enhancing
        Descending Pain ModulationPaul Durham, PhD (ID Number OR07)


    --  12:40 pm - 12:50 pmOne-Year Incidence of Migraine in the US Population:
        Results from the Migraine in America Symptoms and Treatment (MAST)
        StudyRichard B. Lipton, MD, FAHS (ID Number OR08)

Saturday, July 13, 2019

    --  8:00 am - 8:10 amOrally Administered Atogepant was Efficacious, Safe,
        and Tolerable for the Prevention of Migraine: Results from a Phase 2b/3
        StudyDavid Dodick, MD, FAHS (ID Number IOR01)




    --  8:10 am - 8:20 amUbrogepant is Effective for the Acute Treatment of
        Migraine in Patients for whom Triptans are IneffectiveAndrew Blumenfeld,
        MD (ID Number IOR02)




    --  8:20 am - 8:30 amPhase 3 Placebo-Controlled Study of Galcanezumab in
        Patients with Chronic Cluster Headache: Results from 3-Month
        Double-Blind TreatmentTina Oakes, PhD (ID Number IOR03)




    --  8:30 am - 8:40 amNon-invasive Vagus Nerve Stimulation for the Preventive
        Treatment of Episodic Migraine: The Multicenter, Double-blind,
        Randomized, Sham-controlled PREMIUM trialEric Liebler, BA (ID Number
        IOR04)




    --  8:40 am - 8:50 amEfficacy, Safety, and Tolerability of Rimegepant 75 Mg
        Orally Dissolving Tablet for the Acute Treatment of Migraine: Results
        from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial,
        Study 303Richard B. Lipton, MD, FAHS (ID Number IOR05)




    --  8:50 am - 9:00 amEffects of Lasmiditan on Driving Performance: Results
        of 2 Randomized, Blinded, Crossover Simulated Driving Studies with
        Placebo and Active ControlsEric Pearlman, MD, PhD (ID Number IOR06)




    --  9:00 am - 9:10 amMedication Overuse in a Post-hoc Analysis of Phase 3
        Placebo-controlled Studies of Galcanezumab in the Prevention of Episodic
        and Chronic MigraineSheena Aurora, MD (ID Number IOR07)




    --  9:10 am - 9:20 amClinically Meaningful Responses to Fremanezumab in
        Patients with Migraine and Documented Inadequate Response to 2-4 Classes
        of Migraine Preventive Medications in the Multicenter, Randomized,
        Placebo-controlled FOCUS StudyEgilius Spierings, MD, PhD (ID Number
        IOR08)




    --  9:20 am - 9:30 am    Results from the Chronic Migraine Epidemiology and
        Outcomes Study Demonstrate a High Level of Unmet Need for Migraine
        Treatment in People Who Discontinue Acute Prescription Migraine
        MedicationSusan Hutchinson, MD (ID Number IOR09)




    --  9:30 am - 9:40 am    Sustained Efficacy and Long-term safety of Erenumab
        in Patients with Episodic Migraine: 4+ year results of a 5-year,
        Open-label Extension StudyMassoud Ashina, MD, PhD (ID Number IOR10)




    --  9:40 am - 9:50 am    Incorporating Remote Electrical Neuromodulation
        (REN) into Usual Care Reduces Acute Migraine Medication UseMichael J.
        Marmura, MD, FAHS (ID Number IOR11)




    --  9:50 am - 10:00 am  First Non-invasive Combined Occipital & Trigeminal
        Nerve Stimulation Digital Therapeutics System for Treatment of Migraine:
        A Randomized, Sham-controlled, Double-blind Clinical TrialEran Schenker
        (ID Number LBIOR12)




    --  10:30 am - 10:40 am               Testing the Impact of Post-traumatic
        Headache on Headache Complexity in a Sample of SoldiersAnn Scher, PhD
        (ID Number OR09)




    --  10:40 am - 10:50 am               Opioid Use Among People with Migraine:
        Results of the OVERCOME StudySait Ashina, MD (ID Number OR10)




    --  10:50 am - 11:00 am               Rates and Predictors of Using Opioids
        in the Emergency Department to Treat Migraine in Adolescents and Young
        AdultsJennifer Bickel, MD (ID Number OR11)




    --  11:00 am - 11:10 am               Cerebral and Systemic Angiopathy in
        Middle-aged People with MigraineKen Ikeda, MD, PhD (ID Number OR12)




    --  11:10 am - 11:20 am               Characterization of the Effects of the
        Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists, Atogepant
        and Ubrogepant, on Isolated Human Coronary, Cerebral, and Middle
        Meningeal ArteriesEloísa Rubio-Beltran, PhD (ID Number OR13)




    --  11:20 am - 11:30 am               White Light Exposure and Risk of
        Headache Onset among Patients with Episodic MigraineSuzanne Bertisch,
        MD, MPH (ID Number LBOR-02)




    --  11:30 am - 11:40 am               Extracranial Injections of
        OnabotulinumtoxinA in Combination with Intravenous Injection of
        Atogepant Attenuates Activation and Sensitization of HT and WDR Neurons
        by CSDAgustin Melo-Carrillo, MD, PhD (ID Number LBOR-03)




    --  11:40 am - 11:50 am               Intake of Riboflavin (Vitamin B2) and
        the Occurrence of Migraine: A Cross-sectional Analysis of the National
        Health and Nutrition Examination Survey (NHANES) 2001 to 2004
        DatabaseMargaret Slavin, PhD, RD (ID Number LBOR-04)




    --  2:15 pm - 2:25 pm   Cutaneous Heat Pain and Light-Induced Pain
        Thresholds in Post-traumatic Headache Attributed to Mild Traumatic Brain
        InjuryAmaal Starling, MD, FAHS (ID Number OR14)




    --  2:25 pm - 2:35 pm   Stigmatizing Attitudes about Migraine by People
        without Migraine: Results of the OVERCOME StudyRobert Shapiro, MD, PhD,
        FAHS (ID Number OR15)




    --  2:35 pm - 2:45 pm   Pubertal Maturation and Its Association with
        Migraine Headache in Adolescent GirlsVincent Martin, MD, FAHS (ID Number
        OR16)




    --  2:45 pm - 2:55 pm   Migraine Care Across the Healthcare Landscape in the
        United States Among Those with >=4 Migraine Headache Days Per Month:
        Results of the OVERCOME StudyDawn Buse, PhD, FAHS (ID Number OR17)




    --  2:55 pm - 3:05 pm   Central Sites Controlling CGRP-induced
        Light-aversive BehaviorLevi Sowers, PhD (ID Number OR18)




    --  3:05 pm - 3:15 pm   Headache Treatment Pattern and Co-morbid Health
        Burden Associated with Emergency Department and Urgent Care Use in
        People with Migraine: Survey Results from Migraine in America Symptoms
        and Treatment StudyTodd Schwedt, MD, MSCI, FAHS (ID Number OR19)


    --  3:15 pm - 3:25 pm   Social Network Analysis of Young Adolescents with
        MigraineShuu-Jiun Wang, MD, FAHS (ID Number OR20)

Following is a select list of abstracts that will be presented as posters:

    --  P01 Central Mechanisms of Cortical Spreading Depression Inhibition by
        Vagus Nerve StimulationMorais, Andreia

    --  P02 Cortical Spreading Depression Inhibition by Non-invasive Vagus Nerve
        Stimulation: Dose-response and Duration of EffectMorais, Andreia

    --  P03 Early Life Stress-induced Increases in Cortical Spreading Depression
        Susceptibility and Anxiety Are Not Expressed in the Progeny of Stressed
        Male RatsCollins, Stuart

    --  P06 Noninvasive Vagus Nerve Stimulation and Morphine Transiently Inhibit
        Trigeminal Pain Signaling in a Chronic Migraine ModelDurham, Paul

    --  P09 CGRP Antibodies as Adjunctive Prophylactic Therapy for Prolonging
        the Therapeutic Effect of OnabotulinumtoxinA Injections Among Chronic
        Migraine PatientsYuan, Heidi
    --  P12 Eptinezumab Reduces the Frequency of Headaches and Migraines in
        Patients with Episodic or Chronic Migraine: Results from the PRO

    --  P13 OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue
        Topiramate: Results of the FORWARD StudyRothrock, John

    --  P15 Multiple Sclerosis and Headache: A Further Examination of These
        Comorbid Conditions in Patients Receiving Care in a Multiple Sclerosis
        Center: A Cross-Sectional StudyMinen, Mia

    --  P16 Reduced Impact of Headaches after Migraine Preventive Treatment with
        Eptinezumab in Patients with Chronic Migraine: Results from the PREVAIL
        Open-Label Safety StudySpierings, Egilius

    --  P17 Eptinezumab Treatment for Migraine Prevention Reduces Migraine
        Disability in Patients with Chronic Migraine: An Analysis from the
        PREVAIL Open-Label Safety StudyKudrow, David

    --  P18 The Effect of Lacosamide on Chronic Migraine: Retrospective Analysis
        in a Single Center Academic Headache CenterYuan, Heidi

    --  P19 Early Prescribing Patterns of the Anti-Calcitonin Gene-Related
        Peptide Monoclonal Antibodies Are Dominated by Adjunctive Use for
        Episodic and Chronic Migraine Prevention: Trending the First Year of US
        AdoptionSchobel, Virginia

    --  P22 Impact of US Physicians' Perceptions of the Distinct Pharmacological
        and Clinical Characteristics of the Novel Anti-Calcitonin Gene-Related
        Peptide Monoclonal Antibodies on Self-Reported Chronic Migraine
        Prevention Brand ShareSchobel, Virginia

    --  P23 Effectiveness of Erenumbab-aooe on High Frequency Migraine Patients
        in a Tertiary CenterPreston, Juliette

    --  P25 Longitudinal Preventive Medication Use Patterns in Patients
        Receiving OnabotulinumtoxinA Treatment: A Chart Review StudyBurch,
        Rebecca

    --  P28 A Survey of American Headache Society Members on Treatment of
        Migraine in PregnancyHamilton, Katherine

    --  P29 Elective Hospitalizations for Intractable Headache: Outcomes and
        Response PredictorsKiarashi, Jessica

    --  P30 DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of
        Episodic Migraine: Efficacy Results from Two Phase III Randomized,
        Double-blind, Placebo-controlled StudiesLipton, Richard

    --  P35 Long-Term Safety of Fremanezumab: Results of a 1-Year StudyNing,
        Xiaoping

    --  P38 Post-Market Observational Study of Patient Experience with
        ErenumabRobblee, Jennifer

    --  P39 Changes in MIDAS, Perceived Stress, Frontalis Muscle Activity and
        NSAID Usage in Patients with Migraine Headache Without Aura Following
        Ayurveda and Yoga Compared to Controls: An Open Labeled Non-randomized
        StudySharma, Vasudha

    --  P41 Rimegepant 75 Mg Demonstrates Superiority to Placebo on Nausea
        Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in
        the Acute Treatment of MigraineCroop, Robert

    --  P45 The Impact of Shift Work on Migraine: A Case Series and Literature
        ReviewSandoe, Claire

    --  P51 Prevalence of Gastric Ulcer Disease (UD) and Association with NSAID
        Use Among Persons with Migraine: Results from the Migraine in America
        Symptoms and Treatment (MAST) StudyLipton, Richard

    --  P52 Understanding Practice Patterns Surrounding the Use of Hormonal
        Therapies in Migraine: results from the Women's Health Migraine
        SurveyGrosberg, Brian

    --  P53 Who Is Eligible for Novel Medications Designed for the Acute
        Treatment of Migraine and What Are Their Unmet Needs? Results of the
        OVERCOME StudyLipton, Richard

    --  P54 Impact of Migraine Headache Day Frequency on Associated Health :
        Results from the 2017 Migraine in America Symptoms and Treatment (MAST)
        StudyLipton, Richard

    --  P56 Symptom Patterns, Disability, and Physician Visits Among a US Sample
        of People with Migraine: Results of the OVERCOME StudyReed, Michael

    --  P57 A Real-World Analysis of the Burden of Migraine in Patients with
        Prior Treatment Failure: Evidence from the BECOME StudyLucas, Christian

    --  P60 Evaluating the Relationship of Healthcare Professional-Patient
        Communication, Treatment and Satisfaction: Results from Migraine in
        America Symptoms and Treatment StudyBuse, Dawn

    --  P62 Characteristics of Migraine Patients Visiting the European Headache
        Specialist Centers: Real-World Evidence from the Multinational BECOME
        StudyPozo-Rosich, Patricia

    --  P64 Factors Associated with Most Bothersome Non-Headache Migraine
        Symptom (Nausea, Photophobia and Phonophobia): Results from the Migraine
        in America Symptoms and Treatment (MAST) StudyMunjal, Sagar

    --  P68 Prevalence and Incremental Healthcare Costs of Comorbid Depression
        in Migraine CareKee, Arianna

    --  P70 Epidemiology of Headache in Latin America: A Systematic Review and
        Meta-analysis of Its Prevalence and IncidencePacheco-Barrios, Kevin

    --  P73 Economic Aspects of Establishing Prior Use of Two Oral Triptans
        Before Starting Novel Acute Treatments for MigrainePohl, Gerhardt

    --  P74 Impact of Migraine on the Prevalence and Clinical Presentation of
        Depression: A Population-based StudyChu, Min Kyung

    --  P76 Systematic Review of Clinical Studies Evaluating Non-invasive
        Neuromodulation for Migraine and Cluster HeadacheReuter, Uwe

    --  P77 Scoping Review of Migraine and Air Pollution StudiesPortt, Andrea

    --  P80 Paracetamol versus Ibuprofen for the Acute Treatment of Migraine
        Headache in ChildrenVasudevan, Pavithra

    --  P81 Pediatric Screen Exposure and Headache DisabilityLangdon, Raquel

    --  P83 Prognosis of New Daily Persistent Headache in Children and
        AdolescentsSimmons, Adrienne

    --  P84 Title: Headache Prevalence in Transgender Youth: A Retrospective
        Chart ReviewHranilovich, Jennifer

Online Annual Meeting Press Room
Visit https://americanheadachesociety.org/events/61st-annual-scientific-meeting/ for press guidelines and releases, as well as information on press room, press passes, embargo policies and photo/video policy.

About Migraine
Migraine is a disabling neurological disease that affects more than 37 million women, men, and children in the United States. Migraine impacts one in four households, one in five women, one in sixteen men and one in eleven children in the United States. Globally, migraine affects one billion people. In fact, the World Health Organization recognizes migraine as one of the top ten most disabling diseases in the world. Living with migraine is disabling and tends to impact individuals in their most prime years of life. The debilitating nature of migraine is mostly caused by its symptoms, which can vary from person to person and from one migraine attack to another. Migraine attacks may include symptoms like nausea, sensitivity to light, sensitivity to odors, skin sensitivity, fatigue, mood change, dizziness, difficulty concentrating, changes in speech, neck pain and changes in vision (aura) that may include seeing spots, stars, lines, flashing lights, and zigzag lines. Unlike other chronic illnesses, migraine does not have a test that will lead to a diagnosis. Alongside the many physicians and advanced practice providers, patient advocates and patient advocacy organizations are working each day to ensure those living with migraine have an accurate diagnosis, proper treatment plans, and are driving awareness to ensure research is appropriately focused on finding targeted therapies. The goals of the physicians, advanced practice providers and patient advocates supporting those living with migraine are to ensure that no person living with migraine is alone and that they have access to accurate information and credible resources.

About the American Headache Society
The American Headache Society (AHS) is a professional society of healthcare providers dedicated to the study and treatment of headache and face pain. The Society's objectives are to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals and the public and encouraging scientific research are the primary functions of this organization. AHS activities include an annual scientific meeting, a comprehensive headache symposium, regional symposia for neurologists and family practice physicians, and publication of the journal Headache. More information can be found at www.americanheadachesociety.org. In 2010 AHS founded the American Migraine Foundation (AMF) to provide access to information and resources for individuals living with migraine, as well as their loved ones. AMF is dedicated to the advancement of research and awareness surrounding migraine, with a mission to mobilize a community for patient support and advocacy, as well as drive and support impactful research that translates into treatment advances for patients with migraine and other disabling diseases that cause severe head pain. Patients can learn more, find help and get connected by visiting www.americanmigrainefoundation.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/global-leaders-in-migraine-research-to-convene-at-the-american-headache-society-61st-annual-scientific-meeting-300874791.html

SOURCE American Headache Society